Prostate Cancer Drugs-Global Market Status & Trend Report 2013-2023 Top 20 Countries Data
Report Summary
Prostate Cancer Drugs-Global Market Status & Trend Report 2013-2023 Top 20 Countries Data offers a comprehensive analysis on Prostate Cancer Drugs industry, standing on the readers? perspective, delivering detailed market data in Global major 20 countries and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Worldwide and Top 20 Countries Market Size of Prostate Cancer Drugs 2013-2017, and development forecast 2018-2023
Main manufacturers/suppliers of Prostate Cancer Drugs worldwide and market share by regions, with company and product introduction, position in the Prostate Cancer Drugs market
Market status and development trend of Prostate Cancer Drugs by types and applications
Cost and profit status of Prostate Cancer Drugs, and marketing status
Market growth drivers and challenges
The report segments the global Prostate Cancer Drugs market as:
Global Prostate Cancer Drugs Market: Regional Segment Analysis (Regional Production Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
North America (United States, Canada and Mexico)
Europe (Germany, UK, France, Italy, Russia, Spain and Benelux)
Asia Pacific (China, Japan, India, Southeast Asia and Australia)
Latin America (Brazil, Argentina and Colombia)
Middle East and Africa
Global Prostate Cancer Drugs Market: Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Hormonal Therapy
Chemotherapy
Immunotherapy
Targeted Therapy
Global Prostate Cancer Drugs Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Clinics
Hospitals
Other
Global Prostate Cancer Drugs Market: Manufacturers Segment Analysis (Company and Product introduction, Prostate Cancer Drugs Sales Volume, Revenue, Price and Gross Margin):
AbbVie
Astellas Pharma
Astra Zeneca
Johnson & Johnson
Sanofi
GlaxoSmithKline
Merck Group
Novartis
Amgen
Bayer HealthCare
Ferring Pharmaceutical
Janssen Pharmaceuticals
Endo Pharmaceuticals
BMS
Takeda Pharmaceuticals
Northwest Biotherapeutics
Teva Pharmaceutical
Boehringer Ingelheim
Foresee Pharmaceuticals
Tokai Pharmaceuticals
Spectrum Pharmaceuticals
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
Prostate Cancer Drugs-Global Market Status & Trend Report 2013-2023 Top 20 Countries Data offers a comprehensive analysis on Prostate Cancer Drugs industry, standing on the readers? perspective, delivering detailed market data in Global major 20 countries and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Worldwide and Top 20 Countries Market Size of Prostate Cancer Drugs 2013-2017, and development forecast 2018-2023
Main manufacturers/suppliers of Prostate Cancer Drugs worldwide and market share by regions, with company and product introduction, position in the Prostate Cancer Drugs market
Market status and development trend of Prostate Cancer Drugs by types and applications
Cost and profit status of Prostate Cancer Drugs, and marketing status
Market growth drivers and challenges
The report segments the global Prostate Cancer Drugs market as:
Global Prostate Cancer Drugs Market: Regional Segment Analysis (Regional Production Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
North America (United States, Canada and Mexico)
Europe (Germany, UK, France, Italy, Russia, Spain and Benelux)
Asia Pacific (China, Japan, India, Southeast Asia and Australia)
Latin America (Brazil, Argentina and Colombia)
Middle East and Africa
Global Prostate Cancer Drugs Market: Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Hormonal Therapy
Chemotherapy
Immunotherapy
Targeted Therapy
Global Prostate Cancer Drugs Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Clinics
Hospitals
Other
Global Prostate Cancer Drugs Market: Manufacturers Segment Analysis (Company and Product introduction, Prostate Cancer Drugs Sales Volume, Revenue, Price and Gross Margin):
AbbVie
Astellas Pharma
Astra Zeneca
Johnson & Johnson
Sanofi
GlaxoSmithKline
Merck Group
Novartis
Amgen
Bayer HealthCare
Ferring Pharmaceutical
Janssen Pharmaceuticals
Endo Pharmaceuticals
BMS
Takeda Pharmaceuticals
Northwest Biotherapeutics
Teva Pharmaceutical
Boehringer Ingelheim
Foresee Pharmaceuticals
Tokai Pharmaceuticals
Spectrum Pharmaceuticals
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
CHAPTER 1 OVERVIEW OF PROSTATE CANCER DRUGS
1.1 Definition of Prostate Cancer Drugs in This Report
1.2 Commercial Types of Prostate Cancer Drugs
1.2.1 Hormonal Therapy
1.2.2 Chemotherapy
1.2.3 Immunotherapy
1.2.4 Targeted Therapy
1.3 Downstream Application of Prostate Cancer Drugs
1.3.1 Clinics
1.3.2 Hospitals
1.3.3 Other
1.4 Development History of Prostate Cancer Drugs
1.5 Market Status and Trend of Prostate Cancer Drugs 2013-2023
1.5.1 Global Prostate Cancer Drugs Market Status and Trend 2013-2023
1.5.2 Regional Prostate Cancer Drugs Market Status and Trend 2013-2023
CHAPTER 2 GLOBAL MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Development of Prostate Cancer Drugs 2013-2017
2.2 Sales Market of Prostate Cancer Drugs by Regions
2.2.1 Sales Volume of Prostate Cancer Drugs by Regions
2.2.2 Sales Value of Prostate Cancer Drugs by Regions
2.3 Production Market of Prostate Cancer Drugs by Regions
2.4 Global Market Forecast of Prostate Cancer Drugs 2018-2023
2.4.1 Global Market Forecast of Prostate Cancer Drugs 2018-2023
2.4.2 Market Forecast of Prostate Cancer Drugs by Regions 2018-2023
CHAPTER 3 GLOBAL MARKET STATUS AND FORECAST BY TYPES
3.1 Sales Volume of Prostate Cancer Drugs by Types
3.2 Sales Value of Prostate Cancer Drugs by Types
3.3 Market Forecast of Prostate Cancer Drugs by Types
CHAPTER 4 GLOBAL MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Global Sales Volume of Prostate Cancer Drugs by Downstream Industry
4.2 Global Market Forecast of Prostate Cancer Drugs by Downstream Industry
CHAPTER 5 NORTH AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
5.1 North America Prostate Cancer Drugs Market Status by Countries
5.1.1 North America Prostate Cancer Drugs Sales by Countries (2013-2017)
5.1.2 North America Prostate Cancer Drugs Revenue by Countries (2013-2017)
5.1.3 United States Prostate Cancer Drugs Market Status (2013-2017)
5.1.4 Canada Prostate Cancer Drugs Market Status (2013-2017)
5.1.5 Mexico Prostate Cancer Drugs Market Status (2013-2017)
5.2 North America Prostate Cancer Drugs Market Status by Manufacturers
5.3 North America Prostate Cancer Drugs Market Status by Type (2013-2017)
5.3.1 North America Prostate Cancer Drugs Sales by Type (2013-2017)
5.3.2 North America Prostate Cancer Drugs Revenue by Type (2013-2017)
5.4 North America Prostate Cancer Drugs Market Status by Downstream Industry (2013-2017)
CHAPTER 6 EUROPE MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
6.1 Europe Prostate Cancer Drugs Market Status by Countries
6.1.1 Europe Prostate Cancer Drugs Sales by Countries (2013-2017)
6.1.2 Europe Prostate Cancer Drugs Revenue by Countries (2013-2017)
6.1.3 Germany Prostate Cancer Drugs Market Status (2013-2017)
6.1.4 UK Prostate Cancer Drugs Market Status (2013-2017)
6.1.5 France Prostate Cancer Drugs Market Status (2013-2017)
6.1.6 Italy Prostate Cancer Drugs Market Status (2013-2017)
6.1.7 Russia Prostate Cancer Drugs Market Status (2013-2017)
6.1.8 Spain Prostate Cancer Drugs Market Status (2013-2017)
6.1.9 Benelux Prostate Cancer Drugs Market Status (2013-2017)
6.2 Europe Prostate Cancer Drugs Market Status by Manufacturers
6.3 Europe Prostate Cancer Drugs Market Status by Type (2013-2017)
6.3.1 Europe Prostate Cancer Drugs Sales by Type (2013-2017)
6.3.2 Europe Prostate Cancer Drugs Revenue by Type (2013-2017)
6.4 Europe Prostate Cancer Drugs Market Status by Downstream Industry (2013-2017)
CHAPTER 7 ASIA PACIFIC MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
7.1 Asia Pacific Prostate Cancer Drugs Market Status by Countries
7.1.1 Asia Pacific Prostate Cancer Drugs Sales by Countries (2013-2017)
7.1.2 Asia Pacific Prostate Cancer Drugs Revenue by Countries (2013-2017)
7.1.3 China Prostate Cancer Drugs Market Status (2013-2017)
7.1.4 Japan Prostate Cancer Drugs Market Status (2013-2017)
7.1.5 India Prostate Cancer Drugs Market Status (2013-2017)
7.1.6 Southeast Asia Prostate Cancer Drugs Market Status (2013-2017)
7.1.7 Australia Prostate Cancer Drugs Market Status (2013-2017)
7.2 Asia Pacific Prostate Cancer Drugs Market Status by Manufacturers
7.3 Asia Pacific Prostate Cancer Drugs Market Status by Type (2013-2017)
7.3.1 Asia Pacific Prostate Cancer Drugs Sales by Type (2013-2017)
7.3.2 Asia Pacific Prostate Cancer Drugs Revenue by Type (2013-2017)
7.4 Asia Pacific Prostate Cancer Drugs Market Status by Downstream Industry (2013-2017)
CHAPTER 8 LATIN AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
8.1 Latin America Prostate Cancer Drugs Market Status by Countries
8.1.1 Latin America Prostate Cancer Drugs Sales by Countries (2013-2017)
8.1.2 Latin America Prostate Cancer Drugs Revenue by Countries (2013-2017)
8.1.3 Brazil Prostate Cancer Drugs Market Status (2013-2017)
8.1.4 Argentina Prostate Cancer Drugs Market Status (2013-2017)
8.1.5 Colombia Prostate Cancer Drugs Market Status (2013-2017)
8.2 Latin America Prostate Cancer Drugs Market Status by Manufacturers
8.3 Latin America Prostate Cancer Drugs Market Status by Type (2013-2017)
8.3.1 Latin America Prostate Cancer Drugs Sales by Type (2013-2017)
8.3.2 Latin America Prostate Cancer Drugs Revenue by Type (2013-2017)
8.4 Latin America Prostate Cancer Drugs Market Status by Downstream Industry (2013-2017)
CHAPTER 9 MIDDLE EAST AND AFRICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
9.1 Middle East and Africa Prostate Cancer Drugs Market Status by Countries
9.1.1 Middle East and Africa Prostate Cancer Drugs Sales by Countries (2013-2017)
9.1.2 Middle East and Africa Prostate Cancer Drugs Revenue by Countries (2013-2017)
9.1.3 Middle East Prostate Cancer Drugs Market Status (2013-2017)
9.1.4 Africa Prostate Cancer Drugs Market Status (2013-2017)
9.2 Middle East and Africa Prostate Cancer Drugs Market Status by Manufacturers
9.3 Middle East and Africa Prostate Cancer Drugs Market Status by Type (2013-2017)
9.3.1 Middle East and Africa Prostate Cancer Drugs Sales by Type (2013-2017)
9.3.2 Middle East and Africa Prostate Cancer Drugs Revenue by Type (2013-2017)
9.4 Middle East and Africa Prostate Cancer Drugs Market Status by Downstream Industry (2013-2017)
CHAPTER 10 MARKET DRIVING FACTOR ANALYSIS OF PROSTATE CANCER DRUGS
10.1 Global Economy Situation and Trend Overview
10.2 Prostate Cancer Drugs Downstream Industry Situation and Trend Overview
CHAPTER 11 PROSTATE CANCER DRUGS MARKET COMPETITION STATUS BY MAJOR MANUFACTURERS
11.1 Production Volume of Prostate Cancer Drugs by Major Manufacturers
11.2 Production Value of Prostate Cancer Drugs by Major Manufacturers
11.3 Basic Information of Prostate Cancer Drugs by Major Manufacturers
11.3.1 Headquarters Location and Established Time of Prostate Cancer Drugs Major Manufacturer
11.3.2 Employees and Revenue Level of Prostate Cancer Drugs Major Manufacturer
11.4 Market Competition News and Trend
11.4.1 Merger, Consolidation or Acquisition News
11.4.2 Investment or Disinvestment News
11.4.3 New Product Development and Launch
CHAPTER 12 PROSTATE CANCER DRUGS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
12.1 AbbVie
12.1.1 Company profile
12.1.2 Representative Prostate Cancer Drugs Product
12.1.3 Prostate Cancer Drugs Sales, Revenue, Price and Gross Margin of AbbVie
12.2 Astellas Pharma
12.2.1 Company profile
12.2.2 Representative Prostate Cancer Drugs Product
12.2.3 Prostate Cancer Drugs Sales, Revenue, Price and Gross Margin of Astellas Pharma
12.3 Astra Zeneca
12.3.1 Company profile
12.3.2 Representative Prostate Cancer Drugs Product
12.3.3 Prostate Cancer Drugs Sales, Revenue, Price and Gross Margin of Astra Zeneca
12.4 Johnson & Johnson
12.4.1 Company profile
12.4.2 Representative Prostate Cancer Drugs Product
12.4.3 Prostate Cancer Drugs Sales, Revenue, Price and Gross Margin of Johnson & Johnson
12.5 Sanofi
12.5.1 Company profile
12.5.2 Representative Prostate Cancer Drugs Product
12.5.3 Prostate Cancer Drugs Sales, Revenue, Price and Gross Margin of Sanofi
12.6 GlaxoSmithKline
12.6.1 Company profile
12.6.2 Representative Prostate Cancer Drugs Product
12.6.3 Prostate Cancer Drugs Sales, Revenue, Price and Gross Margin of GlaxoSmithKline
12.7 Merck Group
12.7.1 Company profile
12.7.2 Representative Prostate Cancer Drugs Product
12.7.3 Prostate Cancer Drugs Sales, Revenue, Price and Gross Margin of Merck Group
12.8 Novartis
12.8.1 Company profile
12.8.2 Representative Prostate Cancer Drugs Product
12.8.3 Prostate Cancer Drugs Sales, Revenue, Price and Gross Margin of Novartis
12.9 Amgen
12.9.1 Company profile
12.9.2 Representative Prostate Cancer Drugs Product
12.9.3 Prostate Cancer Drugs Sales, Revenue, Price and Gross Margin of Amgen
12.10 Bayer HealthCare
12.10.1 Company profile
12.10.2 Representative Prostate Cancer Drugs Product
12.10.3 Prostate Cancer Drugs Sales, Revenue, Price and Gross Margin of Bayer HealthCare
12.11 Ferring Pharmaceutical
12.11.1 Company profile
12.11.2 Representative Prostate Cancer Drugs Product
12.11.3 Prostate Cancer Drugs Sales, Revenue, Price and Gross Margin of Ferring Pharmaceutical
12.12 Janssen Pharmaceuticals
12.12.1 Company profile
12.12.2 Representative Prostate Cancer Drugs Product
12.12.3 Prostate Cancer Drugs Sales, Revenue, Price and Gross Margin of Janssen Pharmaceuticals
12.13 Endo Pharmaceuticals
12.13.1 Company profile
12.13.2 Representative Prostate Cancer Drugs Product
12.13.3 Prostate Cancer Drugs Sales, Revenue, Price and Gross Margin of Endo Pharmaceuticals
12.14 BMS
12.14.1 Company profile
12.14.2 Representative Prostate Cancer Drugs Product
12.14.3 Prostate Cancer Drugs Sales, Revenue, Price and Gross Margin of BMS
12.15 Takeda Pharmaceuticals
12.15.1 Company profile
12.15.2 Representative Prostate Cancer Drugs Product
12.15.3 Prostate Cancer Drugs Sales, Revenue, Price and Gross Margin of Takeda Pharmaceuticals
12.16 Northwest Biotherapeutics
12.17 Teva Pharmaceutical
12.18 Boehringer Ingelheim
12.19 Foresee Pharmaceuticals
12.20 Tokai Pharmaceuticals
12.21 Spectrum Pharmaceuticals
CHAPTER 13 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF PROSTATE CANCER DRUGS
13.1 Industry Chain of Prostate Cancer Drugs
13.2 Upstream Market and Representative Companies Analysis
13.3 Downstream Market and Representative Companies Analysis
CHAPTER 14 COST AND GROSS MARGIN ANALYSIS OF PROSTATE CANCER DRUGS
14.1 Cost Structure Analysis of Prostate Cancer Drugs
14.2 Raw Materials Cost Analysis of Prostate Cancer Drugs
14.3 Labor Cost Analysis of Prostate Cancer Drugs
14.4 Manufacturing Expenses Analysis of Prostate Cancer Drugs
CHAPTER 15 REPORT CONCLUSION
CHAPTER 16 RESEARCH METHODOLOGY AND REFERENCE
16.1 Methodology/Research Approach
16.1.1 Research Programs/Design
16.1.2 Market Size Estimation
16.1.3 Market Breakdown and Data Triangulation
16.2 Data Source
16.2.1 Secondary Sources
16.2.2 Primary Sources
16.3 Reference
1.1 Definition of Prostate Cancer Drugs in This Report
1.2 Commercial Types of Prostate Cancer Drugs
1.2.1 Hormonal Therapy
1.2.2 Chemotherapy
1.2.3 Immunotherapy
1.2.4 Targeted Therapy
1.3 Downstream Application of Prostate Cancer Drugs
1.3.1 Clinics
1.3.2 Hospitals
1.3.3 Other
1.4 Development History of Prostate Cancer Drugs
1.5 Market Status and Trend of Prostate Cancer Drugs 2013-2023
1.5.1 Global Prostate Cancer Drugs Market Status and Trend 2013-2023
1.5.2 Regional Prostate Cancer Drugs Market Status and Trend 2013-2023
CHAPTER 2 GLOBAL MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Development of Prostate Cancer Drugs 2013-2017
2.2 Sales Market of Prostate Cancer Drugs by Regions
2.2.1 Sales Volume of Prostate Cancer Drugs by Regions
2.2.2 Sales Value of Prostate Cancer Drugs by Regions
2.3 Production Market of Prostate Cancer Drugs by Regions
2.4 Global Market Forecast of Prostate Cancer Drugs 2018-2023
2.4.1 Global Market Forecast of Prostate Cancer Drugs 2018-2023
2.4.2 Market Forecast of Prostate Cancer Drugs by Regions 2018-2023
CHAPTER 3 GLOBAL MARKET STATUS AND FORECAST BY TYPES
3.1 Sales Volume of Prostate Cancer Drugs by Types
3.2 Sales Value of Prostate Cancer Drugs by Types
3.3 Market Forecast of Prostate Cancer Drugs by Types
CHAPTER 4 GLOBAL MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Global Sales Volume of Prostate Cancer Drugs by Downstream Industry
4.2 Global Market Forecast of Prostate Cancer Drugs by Downstream Industry
CHAPTER 5 NORTH AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
5.1 North America Prostate Cancer Drugs Market Status by Countries
5.1.1 North America Prostate Cancer Drugs Sales by Countries (2013-2017)
5.1.2 North America Prostate Cancer Drugs Revenue by Countries (2013-2017)
5.1.3 United States Prostate Cancer Drugs Market Status (2013-2017)
5.1.4 Canada Prostate Cancer Drugs Market Status (2013-2017)
5.1.5 Mexico Prostate Cancer Drugs Market Status (2013-2017)
5.2 North America Prostate Cancer Drugs Market Status by Manufacturers
5.3 North America Prostate Cancer Drugs Market Status by Type (2013-2017)
5.3.1 North America Prostate Cancer Drugs Sales by Type (2013-2017)
5.3.2 North America Prostate Cancer Drugs Revenue by Type (2013-2017)
5.4 North America Prostate Cancer Drugs Market Status by Downstream Industry (2013-2017)
CHAPTER 6 EUROPE MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
6.1 Europe Prostate Cancer Drugs Market Status by Countries
6.1.1 Europe Prostate Cancer Drugs Sales by Countries (2013-2017)
6.1.2 Europe Prostate Cancer Drugs Revenue by Countries (2013-2017)
6.1.3 Germany Prostate Cancer Drugs Market Status (2013-2017)
6.1.4 UK Prostate Cancer Drugs Market Status (2013-2017)
6.1.5 France Prostate Cancer Drugs Market Status (2013-2017)
6.1.6 Italy Prostate Cancer Drugs Market Status (2013-2017)
6.1.7 Russia Prostate Cancer Drugs Market Status (2013-2017)
6.1.8 Spain Prostate Cancer Drugs Market Status (2013-2017)
6.1.9 Benelux Prostate Cancer Drugs Market Status (2013-2017)
6.2 Europe Prostate Cancer Drugs Market Status by Manufacturers
6.3 Europe Prostate Cancer Drugs Market Status by Type (2013-2017)
6.3.1 Europe Prostate Cancer Drugs Sales by Type (2013-2017)
6.3.2 Europe Prostate Cancer Drugs Revenue by Type (2013-2017)
6.4 Europe Prostate Cancer Drugs Market Status by Downstream Industry (2013-2017)
CHAPTER 7 ASIA PACIFIC MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
7.1 Asia Pacific Prostate Cancer Drugs Market Status by Countries
7.1.1 Asia Pacific Prostate Cancer Drugs Sales by Countries (2013-2017)
7.1.2 Asia Pacific Prostate Cancer Drugs Revenue by Countries (2013-2017)
7.1.3 China Prostate Cancer Drugs Market Status (2013-2017)
7.1.4 Japan Prostate Cancer Drugs Market Status (2013-2017)
7.1.5 India Prostate Cancer Drugs Market Status (2013-2017)
7.1.6 Southeast Asia Prostate Cancer Drugs Market Status (2013-2017)
7.1.7 Australia Prostate Cancer Drugs Market Status (2013-2017)
7.2 Asia Pacific Prostate Cancer Drugs Market Status by Manufacturers
7.3 Asia Pacific Prostate Cancer Drugs Market Status by Type (2013-2017)
7.3.1 Asia Pacific Prostate Cancer Drugs Sales by Type (2013-2017)
7.3.2 Asia Pacific Prostate Cancer Drugs Revenue by Type (2013-2017)
7.4 Asia Pacific Prostate Cancer Drugs Market Status by Downstream Industry (2013-2017)
CHAPTER 8 LATIN AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
8.1 Latin America Prostate Cancer Drugs Market Status by Countries
8.1.1 Latin America Prostate Cancer Drugs Sales by Countries (2013-2017)
8.1.2 Latin America Prostate Cancer Drugs Revenue by Countries (2013-2017)
8.1.3 Brazil Prostate Cancer Drugs Market Status (2013-2017)
8.1.4 Argentina Prostate Cancer Drugs Market Status (2013-2017)
8.1.5 Colombia Prostate Cancer Drugs Market Status (2013-2017)
8.2 Latin America Prostate Cancer Drugs Market Status by Manufacturers
8.3 Latin America Prostate Cancer Drugs Market Status by Type (2013-2017)
8.3.1 Latin America Prostate Cancer Drugs Sales by Type (2013-2017)
8.3.2 Latin America Prostate Cancer Drugs Revenue by Type (2013-2017)
8.4 Latin America Prostate Cancer Drugs Market Status by Downstream Industry (2013-2017)
CHAPTER 9 MIDDLE EAST AND AFRICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
9.1 Middle East and Africa Prostate Cancer Drugs Market Status by Countries
9.1.1 Middle East and Africa Prostate Cancer Drugs Sales by Countries (2013-2017)
9.1.2 Middle East and Africa Prostate Cancer Drugs Revenue by Countries (2013-2017)
9.1.3 Middle East Prostate Cancer Drugs Market Status (2013-2017)
9.1.4 Africa Prostate Cancer Drugs Market Status (2013-2017)
9.2 Middle East and Africa Prostate Cancer Drugs Market Status by Manufacturers
9.3 Middle East and Africa Prostate Cancer Drugs Market Status by Type (2013-2017)
9.3.1 Middle East and Africa Prostate Cancer Drugs Sales by Type (2013-2017)
9.3.2 Middle East and Africa Prostate Cancer Drugs Revenue by Type (2013-2017)
9.4 Middle East and Africa Prostate Cancer Drugs Market Status by Downstream Industry (2013-2017)
CHAPTER 10 MARKET DRIVING FACTOR ANALYSIS OF PROSTATE CANCER DRUGS
10.1 Global Economy Situation and Trend Overview
10.2 Prostate Cancer Drugs Downstream Industry Situation and Trend Overview
CHAPTER 11 PROSTATE CANCER DRUGS MARKET COMPETITION STATUS BY MAJOR MANUFACTURERS
11.1 Production Volume of Prostate Cancer Drugs by Major Manufacturers
11.2 Production Value of Prostate Cancer Drugs by Major Manufacturers
11.3 Basic Information of Prostate Cancer Drugs by Major Manufacturers
11.3.1 Headquarters Location and Established Time of Prostate Cancer Drugs Major Manufacturer
11.3.2 Employees and Revenue Level of Prostate Cancer Drugs Major Manufacturer
11.4 Market Competition News and Trend
11.4.1 Merger, Consolidation or Acquisition News
11.4.2 Investment or Disinvestment News
11.4.3 New Product Development and Launch
CHAPTER 12 PROSTATE CANCER DRUGS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
12.1 AbbVie
12.1.1 Company profile
12.1.2 Representative Prostate Cancer Drugs Product
12.1.3 Prostate Cancer Drugs Sales, Revenue, Price and Gross Margin of AbbVie
12.2 Astellas Pharma
12.2.1 Company profile
12.2.2 Representative Prostate Cancer Drugs Product
12.2.3 Prostate Cancer Drugs Sales, Revenue, Price and Gross Margin of Astellas Pharma
12.3 Astra Zeneca
12.3.1 Company profile
12.3.2 Representative Prostate Cancer Drugs Product
12.3.3 Prostate Cancer Drugs Sales, Revenue, Price and Gross Margin of Astra Zeneca
12.4 Johnson & Johnson
12.4.1 Company profile
12.4.2 Representative Prostate Cancer Drugs Product
12.4.3 Prostate Cancer Drugs Sales, Revenue, Price and Gross Margin of Johnson & Johnson
12.5 Sanofi
12.5.1 Company profile
12.5.2 Representative Prostate Cancer Drugs Product
12.5.3 Prostate Cancer Drugs Sales, Revenue, Price and Gross Margin of Sanofi
12.6 GlaxoSmithKline
12.6.1 Company profile
12.6.2 Representative Prostate Cancer Drugs Product
12.6.3 Prostate Cancer Drugs Sales, Revenue, Price and Gross Margin of GlaxoSmithKline
12.7 Merck Group
12.7.1 Company profile
12.7.2 Representative Prostate Cancer Drugs Product
12.7.3 Prostate Cancer Drugs Sales, Revenue, Price and Gross Margin of Merck Group
12.8 Novartis
12.8.1 Company profile
12.8.2 Representative Prostate Cancer Drugs Product
12.8.3 Prostate Cancer Drugs Sales, Revenue, Price and Gross Margin of Novartis
12.9 Amgen
12.9.1 Company profile
12.9.2 Representative Prostate Cancer Drugs Product
12.9.3 Prostate Cancer Drugs Sales, Revenue, Price and Gross Margin of Amgen
12.10 Bayer HealthCare
12.10.1 Company profile
12.10.2 Representative Prostate Cancer Drugs Product
12.10.3 Prostate Cancer Drugs Sales, Revenue, Price and Gross Margin of Bayer HealthCare
12.11 Ferring Pharmaceutical
12.11.1 Company profile
12.11.2 Representative Prostate Cancer Drugs Product
12.11.3 Prostate Cancer Drugs Sales, Revenue, Price and Gross Margin of Ferring Pharmaceutical
12.12 Janssen Pharmaceuticals
12.12.1 Company profile
12.12.2 Representative Prostate Cancer Drugs Product
12.12.3 Prostate Cancer Drugs Sales, Revenue, Price and Gross Margin of Janssen Pharmaceuticals
12.13 Endo Pharmaceuticals
12.13.1 Company profile
12.13.2 Representative Prostate Cancer Drugs Product
12.13.3 Prostate Cancer Drugs Sales, Revenue, Price and Gross Margin of Endo Pharmaceuticals
12.14 BMS
12.14.1 Company profile
12.14.2 Representative Prostate Cancer Drugs Product
12.14.3 Prostate Cancer Drugs Sales, Revenue, Price and Gross Margin of BMS
12.15 Takeda Pharmaceuticals
12.15.1 Company profile
12.15.2 Representative Prostate Cancer Drugs Product
12.15.3 Prostate Cancer Drugs Sales, Revenue, Price and Gross Margin of Takeda Pharmaceuticals
12.16 Northwest Biotherapeutics
12.17 Teva Pharmaceutical
12.18 Boehringer Ingelheim
12.19 Foresee Pharmaceuticals
12.20 Tokai Pharmaceuticals
12.21 Spectrum Pharmaceuticals
CHAPTER 13 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF PROSTATE CANCER DRUGS
13.1 Industry Chain of Prostate Cancer Drugs
13.2 Upstream Market and Representative Companies Analysis
13.3 Downstream Market and Representative Companies Analysis
CHAPTER 14 COST AND GROSS MARGIN ANALYSIS OF PROSTATE CANCER DRUGS
14.1 Cost Structure Analysis of Prostate Cancer Drugs
14.2 Raw Materials Cost Analysis of Prostate Cancer Drugs
14.3 Labor Cost Analysis of Prostate Cancer Drugs
14.4 Manufacturing Expenses Analysis of Prostate Cancer Drugs
CHAPTER 15 REPORT CONCLUSION
CHAPTER 16 RESEARCH METHODOLOGY AND REFERENCE
16.1 Methodology/Research Approach
16.1.1 Research Programs/Design
16.1.2 Market Size Estimation
16.1.3 Market Breakdown and Data Triangulation
16.2 Data Source
16.2.1 Secondary Sources
16.2.2 Primary Sources
16.3 Reference
